Dr. Conway has 30 years of research experience examining the biology of pain mechanisms: 17 years in drug discovery and development at Bristol-Myers Squibb Company, and 6 years as Chief Scientific Officer (CSO) at Biohaven then CSO at Pfizer following their acquisition of the CGRP Migraine Franchise from Biohaven. Dr. Conway dedicated his scientific career to bringing relief to the ~1 billion people worldwide who suffer from migraine. Over two decades, Dr. Conway, has pursued a vision to advance new therapies that would transform migraine treatment by providing rapid onset and durable efficacy, safely (see Dubowchik & Conway et al., 2020; Berman et al., 2020; Mullin et al., 2020). Dr. Conway led the biology program identifying the novel CGRP receptor antagonists rimegepant (see Luo et al., 2012) and zavegepant (see Chaturvedula et al., 2013), and was actively involved in their clinical and regulatory advancements. Dr. Conway developed a non-terminal assay in primates (marmosets), avoiding euthanasia of over 800 animals and yielding $2M in savings (an achievement recognized by the company’s first ever Animal Welfare Award). He leveraged this PK/PD assay to successfully predict the clinically efficacious doses for both rimegepant and zavegepant accelerating their clinical development. Rimegepant is FDA-approved as Nurtec® ODT for acute and preventive treatment of migraine showing rapid 60-minute onset and durable effects through 48 hours with a single oral dose, and significantly reducing migraine days with every other day dosing (see Croop et al., 2019; 2021). Zavegepant, delivered intranasally, demonstrated rapid onset with pain relief as early as 15 minutes and sustained benefits through 48 hours (see Lipton et al., 2023). Zavegepant is FDA-approved as Zavzpret™ for the acute treatment of migraine in adults. Dr. Conway’s extensive research has resulted in being an inventor on multiple granted patents for the treatment of pain and migraine. Dr. Conway has been intimately involved in Neuroscience programs advancing biologic and small molecule assets, including the identification of novel molecules that revealed the benefit of blocking the spinal kinase AAK1 in neuropathic (but not normal) pain states (see Kostich et al., 2016). Dr. Conway is a tech-savvy researcher with a track-record of advancing technology to accelerate high-quality decision making in drug discovery and development. Prior to his time in pharma, Dr. Conway carried out postgraduate studies in the Anesthesiology Research Laboratory under the guidance of Dr. Tony Yaksh at the University of California San Diego where he studied the spinal pharmacology of pain mechanisms demonstrating the critical role of constitutive spinal COX-2 (but not COX-1) in the pain-relieving properties of NSAIDs (see Yaksh et al., 2001). Dr. Conway received his doctoral training in the Laboratory of Psychopharmacology under the tutelage of Dr. Loy Lytle where he earned a Ph.D. in Neuroscience from the University of California Santa Barbara and was first to systematically characterize maturational changes in nociception, uncovering a root cause of prior discrepancies in the literature and identifying the need to vary both age and stimulus intensity when assessing the presence/absence of drug-responses in immature animals (see Conway et al., 1998). SELECT PUB Lipton, R.B., et al. (2023). "Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine …" Lancet Neurol 22(3): 209-217. Croop, R., et al. (2021). "Oral rimegepant for preventive treatment of migraine …" The Lancet 397(10268): 51-60. Dubowchik, G.M., Conway, C.M. et al. (2020). "Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success." Journal of Medicinal Chemistry 63(13): 6600-6623. Mullin, K., et al. (2020). "Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy." Neurology 94(20): e2121-e2125. Berman, G., et al. (2020). "Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine." Headache 60(8): 1734-1742. Croop, R., et al. (2019). "Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine …" The Lancet 394(10200): 737-745. Kostich, W., et al. (2016). "Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain." Journal of Pharmacology and Experimental Therapeutics 358(3): 371-386. Chaturvedula, P.V., et al. (2013). "Discovery of BMS-742413 …" Bioorganic Medicinal Chemistry Letters 23(11): 3157 Luo, G., et al. (2012). "Discovery of BMS-92771 …” Journal of Medicinal Chemistry 55(23): 10644-10651. Yaksh, T.L., Dirig, D.M., Conway, C.M. et al. (2001). "The acute antihyperalgesic action …" Journal of Neuroscience 21(16): 58 47-5853. Conway, C.M., et al. (1998). "Maturational changes in the thermal …" Developmental Psychobiology 33(1): 47-60.